Simvastatin-ratiopharm®    (DrugBank: Simvastatin)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
162類天疱瘡(後天性表皮水疱症を含む。)1

162. 類天疱瘡(後天性表皮水疱症を含む。) [臨床試験数:70,薬物数:117(DrugBank:46),標的遺伝子数:30,標的パスウェイ数:128
Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 70 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-004361-32-DE
(EUCTR)
26/02/201322/05/2012Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoidEffect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoidA prospective multi-centre randomised double-blind placebo-controlled pilot study - SICOPEM Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal phase with severe itching. Between 10 to 30 percent of patients exhibit mucosal membrane involvement in addition to the skin lesions.;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Trade Name: Simvastatin-ratiopharm®
Product Name: Simvastatin-ratiopharm
Other descriptive name: SIMVASTATIN
Philipps-Universität MarburgNULLNot RecruitingFemale: yes
Male: yes
Germany